Regeneron: There Won't Be a Better Opportunity to Buy, Citigroup Says

Text size

Regeneron (REGN) has surged during the past three months, trumping Biogen Idec (BIIB), Amgen, Gilead Sciences and Celgene. But don't let its recent run concern you, Citigroup say. Now is still the best time to buy.

Shares of Regeneron have gained 28% during the past three month of trading, besting Biogen Idec's 26% rise, Amgen's 12% advance, Gilead Sciences' 1.4% move higher and Celgene's 5.1% drop.